180 Life Sciences Corp.
For the period ended Jun 30, 2025. Filed Jul 23, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Jul 23, 2025
FRMM$2.82-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
| For the Three Months Ended · For the Six Months Ended | ||||
|---|---|---|---|---|
| June 30, | June 30, | |||
| 2025 | 2024 | 2025 | 2024 | |
| Operating Expenses: | ||||
| Research and development | $182,386 | $118,861 | $423,291 | $484,047 |
| Research and development - related parties | 140,372 | 133,665 | 275,827 | 304,207 |
| General and administrative | 1,407,657 | 1,594,212 | 3,404,265 | 3,150,952 |
| Total Operating Expenses | 1,730,415 | 1,846,738 | 4,103,383 | 3,939,206 |
| Loss From Operations | (1,730,415) | (1,846,738) | (4,103,383) | (3,939,206) |
| Other (Expense) Income: | ||||
| Other income | 6,483 | 1,712,702 | 12,874 | 2,752,066 |
| Interest expense | (2,672) | (11,360) | (5,327) | (27,809) |
| Change in fair value of derivative liabilities | - | 249 | - | 58 |
| Gain on settlement of liabilities | - | 156,928 | - | 156,928 |
| Total other (expense) income, net | 3,811 | 1,858,519 | 7,547 | 2,881,243 |
| Income (Loss) Before Income Taxes | (1,726,604) | 11,781 | (4,095,836) | (1,057,963) |
| Income tax benefit | - | - | - | - |
| Net Income (Loss) | (1,726,604) | 11,781 | (4,095,836) | (1,057,963) |
| Deemed Dividend | - | - | - | - |
| Net Income (Loss) Available to Common Stockholders | (1,726,604) | 11,781 | (4,095,836) | (1,057,963) |
| Other Comprehensive Loss: | ||||
| Foreign currency translation adjustments | (143,435) | (20,861) | (208,126) | (14,401) |
| Total Comprehensive Loss | $(1,870,039) | $(9,080) | $(4,303,962) | $(1,072,364) |
| Basic and Diluted Net Income (Loss) per Common Share | ||||
| Basic | $(0.30) | $0.01 | $(0.88) | $(1.42) |
| Diluted | $(0.30) | $0.01 | $(0.88) | $(1.42) |
| Weighted Average Number of Common Shares Outstanding: | ||||
| Basic | 5,708,126 | 919,141 | 4,629,719 | 745,552 |
| Diluted | 5,708,126 | 919,141 | 4,629,719 | 745,552 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.